

Jeremie guedj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5045428/publications.pdf>

Version: 2024-02-01

114
papers

5,154
citations

94269

37
h-index

106150

65
g-index

132
all docs

132
docs citations

132
times ranked

6649
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	3.9	382
2	Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3991-3996.	3.3	298
3	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. <i>Nature</i> , 2020, 585, 584-587.	13.7	287
4	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
5	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	181
6	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	1.3	170
7	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389.	1.3	153
8	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. <i>PLoS Pathogens</i> , 2012, 8, e1002881.	2.1	139
9	Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 907-923.	1.6	135
10	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535.	3.9	108
11	Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. <i>Nature Communications</i> , 2021, 12, 1735.	5.8	105
12	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. <i>The Lancet Global Health</i> , 2017, 5, e80-e88.	2.9	100
13	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. <i>ELife</i> , 2021, 10, .	2.8	97
14	Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration. <i>Hepatology</i> , 2011, 53, 1801-1808.	3.6	90
15	Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8847-8852.	3.3	89
16	Dose regimen of favipiravir for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 150-151.	4.6	86
17	Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. <i>PLoS Computational Biology</i> , 2013, 9, e1002959.	1.5	83
18	Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. <i>Journal of Experimental Medicine</i> , 2012, 209, 1481-1492.	4.2	79

#	ARTICLE	IF	CITATIONS
19	A perspective on modelling hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2010, 17, 825-833.	1.0	76
20	Modelling hepatitis C therapyâ€”predicting effects of treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 437-445.	8.2	72
21	Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. <i>Journal of Theoretical Biology</i> , 2010, 267, 330-340.	0.8	68
22	Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2013, 144, 402-413.e12.	0.6	66
23	Maximum Likelihood Estimation in Dynamical Models of HIV. <i>Biometrics</i> , 2007, 63, 1198-1206.	0.8	60
24	Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. <i>JCI Insight</i> , 2017, 2, e88864.	2.3	60
25	Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferonâ€”alpha therapy via mathematical modeling. <i>Hepatology</i> , 2014, 60, 1902-1910.	3.6	59
26	Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	59
27	Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. <i>Antiviral Therapy</i> , 2012, 17, 1171-1182.	0.6	58
28	Ebola virus dynamics in mice treated with favipiravir. <i>Antiviral Research</i> , 2015, 123, 70-77.	1.9	57
29	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013.	5.8	54
30	Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B. <i>Current Hepatitis Reports</i> , 2011, 10, 214-227.	0.3	52
31	Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). <i>Hepatology</i> , 2012, 55, 1030-1037.	3.6	51
32	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014, 63, 161-169.	6.1	51
33	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020, 26, 1787-1795.	3.2	51
34	Practical Identifiability of HIV Dynamics Models. <i>Bulletin of Mathematical Biology</i> , 2007, 69, 2493-2513.	0.9	48
35	Understanding silibininâ€™s modes of action against HCV using viral kinetic modeling. <i>Journal of Hepatology</i> , 2012, 56, 1019-1024.	1.8	47
36	Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938. <i>Antiviral Therapy</i> , 2014, 19, 211-220.	0.6	44

#	ARTICLE	IF	CITATIONS
37	Favipiravir for children with Ebola. <i>Lancet, The</i> , 2015, 385, 603-604.	6.3	43
38	SARS-CoV-2 viral dynamics in non-human primates. <i>PLoS Computational Biology</i> , 2021, 17, e1008785.	1.5	41
39	Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. <i>PLoS Computational Biology</i> , 2021, 17, e1008752.	1.5	41
40	Estimation of dynamical model parameters taking into account undetectable marker values. <i>BMC Medical Research Methodology</i> , 2006, 6, 38.	1.4	40
41	Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20160130.	1.5	39
42	Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches. <i>AAPS Journal</i> , 2015, 17, 691-699.	2.2	38
43	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	5.8	38
44	Estimating a difference of Kullback-Leibler risks using a normalized difference of AIC. <i>Annals of Applied Statistics</i> , 2008, 2, .	0.5	36
45	Determining Ribavirin's mechanism of action against Lassa virus infection. <i>Scientific Reports</i> , 2017, 7, 11693.	1.6	36
46	Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	35
47	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 2149-2159.	2.5	35
48	Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 188-188.	2.3	34
49	Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted. <i>PLoS Computational Biology</i> , 2014, 10, e1003840.	1.5	32
50	Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer. <i>BMC Medical Research Methodology</i> , 2017, 17, 105.	1.4	28
51	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820.	2.3	27
52	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2376-2380.	1.3	25
53	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	1.3	25
54	Using the SAEM Algorithm for Mechanistic Joint Models Characterizing the Relationship Between Nonlinear PSA Kinetics and Survival in Prostate Cancer Patients. <i>Biometrics</i> , 2017, 73, 305-312.	0.8	24

#	ARTICLE	IF	CITATIONS
55	Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. <i>Hepatology</i> , 2014, 59, 1706-1714.	3.6	23
56	Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. <i>PLoS Computational Biology</i> , 2021, 17, e1008535.	1.5	22
57	The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?. <i>Scientific Reports</i> , 2017, 7, 10233.	1.6	20
58	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.	1.3	20
59	Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. <i>Science Translational Medicine</i> , 2014, 6, 246ra98.	5.8	19
60	What drives the dynamics of HBV RNA during treatment?. <i>Journal of Viral Hepatitis</i> , 2021, 28, 383-392.	1.0	19
61	Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy. <i>Cell Reports</i> , 2022, 39, 110825.	2.9	19
62	Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. <i>BMC Medical Research Methodology</i> , 2013, 13, 60.	1.4	18
63	NIMROD: A program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 111, 447-458.	2.6	18
64	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). <i>Aids</i> , 2015, 29, 2419-2426.	1.0	18
65	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1860-1877.	0.7	17
66	HCV Kinetic Models and Their Implications in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 231-242.	1.3	16
67	Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 665-673.	1.9	16
68	Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. <i>Npj Vaccines</i> , 2018, 3, 36.	2.9	16
69	A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents. <i>Frontiers in Microbiology</i> , 2018, 9, 601.	1.5	16
70	SARS-CoV-2 viral dynamics in infections with Alpha and Beta variants of concern in the French community. <i>Journal of Infection</i> , 2021, , .	1.7	16
71	Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One equals two?. <i>EBioMedicine</i> , 2021, 74, 103663.	2.7	16
72	Design evaluation and optimization for models of hepatitis C viral dynamics. <i>Statistics in Medicine</i> , 2011, 30, 1045-1056.	0.8	14

#	ARTICLE	IF	CITATIONS
73	The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 397-399.	1.4	14
74	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017, 12, e0177352.	1.1	13
75	Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e32-e40.	3.4	13
76	Model Averaging in Viral Dynamic Models. <i>AAPS Journal</i> , 2020, 22, 48.	2.2	12
77	Bayesian inference using Hamiltonian Monte Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. <i>Statistics in Medicine</i> , 2020, 39, 4853-4868.	0.8	11
78	Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1045-1054.	2.3	11
79	Variant-specific SARS-CoV-2 within-host kinetics. <i>Journal of Medical Virology</i> , 2022, 94, 3625-3633.	2.5	11
80	A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 599-608.	2.3	10
81	Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. <i>Antiviral Research</i> , 2020, 177, 104758.	1.9	10
82	Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference. <i>PLoS Computational Biology</i> , 2021, 17, e1008564.	1.5	10
83	Joint Modeling of the Clinical Progression and of the Biomarkers' Dynamics Using a Mechanistic Model. <i>Biometrics</i> , 2011, 67, 59-66.	0.8	9
84	The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1a-infected patients treated with Peg-IFN- α 2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 488-496.	1.0	9
85	Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 803-810.	1.4	9
86	Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of <i>Mycobacterium Avium</i> Complex Infection. <i>Antiviral Therapy</i> , 2006, 11, 343-350.	0.6	9
87	Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved. <i>Hepatology</i> , 2011, 54, 749-749.	3.6	8
88	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	1.4	8
89	Survival of SARS-CoV-2 on Non-Porous Materials in an Experimental Setting Representative of Fomites. <i>Coatings</i> , 2021, 11, 371.	1.2	8
90	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 764-765.	4.6	8

#	ARTICLE	IF	CITATIONS
91	A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. <i>Antiviral Therapy</i> , 2015, 20, 469-477.	0.6	7
92	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1481-1491.	1.4	7
93	High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. <i>Journal of Infection</i> , 2021, 82, 186-230.	1.7	7
94	Modeling the dynamics of biomarkers during primary HIV infection taking into account the uncertainty of infection date. <i>Annals of Applied Statistics</i> , 2010, 4, .	0.5	6
95	Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E302; author reply E303.	3.3	6
96	Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. <i>Antiviral Therapy</i> , 2014, 19, 469-477.	0.6	6
97	Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw235.	0.4	6
98	Acute bacterial or viral infectionâ€”What's the difference? A perspective from PKPD modellers. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1133-1136.	2.8	6
99	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009300.	1.3	6
100	Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1452-1463.	1.1	6
101	Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101055.	0.6	6
102	Chronic use of reninâ€”angiotensinâ€”aldosterone system blockers and mortality in COVIDâ€”19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.0	4
103	Modeling the bacterial dynamics in the gut microbiota following an antibioticâ€”induced perturbation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 906-918.	1.3	4
104	Modelling the Interaction between Danoprevir and Mericitabine in the Treatment of Chronic HCV Infection. <i>Antiviral Therapy</i> , 2016, 21, 297-306.	0.6	2
105	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinicalâ€”pathological study. <i>Digestive and Liver Disease</i> , 2015, 47, 296-302.	0.4	2
106	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trialâ€”authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 277-279.	1.3	2
107	Can we use viral kinetic models to individualize treatment?. <i>Liver International</i> , 2015, 35, 297-298.	1.9	1
108	Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 1115-1116.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Reply. Hepatology, 2015, 61, 2118-2119.	3.6	0
110	Authors' response: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV – some considerations. Antiviral Therapy, 2016, 21, 648-649.	0.6	0
111	Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. , 2021, 17, e1008535.		0
112	Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. , 2021, 17, e1008535.		0
113	Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. , 2021, 17, e1008535.		0
114	Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. , 2021, 17, e1008535.		0